(NASDAQ: SPTX) Seaport Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.35%.
Seaport Therapeutics's earnings in 2026 is N/A.On average, 9 Wall Street analysts forecast SPTX's earnings for 2026 to be -$287,983,653, with the lowest SPTX earnings forecast at -$621,650,277, and the highest SPTX earnings forecast at -$182,673,002. On average, 9 Wall Street analysts forecast SPTX's earnings for 2027 to be -$142,428,734, with the lowest SPTX earnings forecast at -$172,593,199, and the highest SPTX earnings forecast at -$101,172,740.
In 2028, SPTX is forecast to generate -$146,486,350 in earnings, with the lowest earnings forecast at -$194,626,374 and the highest earnings forecast at -$95,552,032.